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Introduction and Background 
THE KIDNEY: HYPERTENSIVE AND ANTI-HYPERTENSIVE ROLES 
The importance of the kidney as a regulator of blood pressure 
has long been recognized. With Goldblatt's discovery in 1934 that 
unilateral nephrectomy and constriction of the contralateral renal 
artery resulted in the development of sustained hypertension in the 
dog^ and the discovery of the renin-angiotensin system, investiga¬ 
tional activity was directed toward elucidation of a possible renal 
pressor role in the pathophysiology of hypertension. At the same 
time, however, evidence began accumulating which pointed toward an 
anti-hypertensive role for the kidney as well and even called into 
question the supposed dominance of the renal pressor hypothesis in 
the pathogenesis of some forms of hypertension. 
Of initial interest was Goldblatt's inability to produce hyper¬ 
tension in dogs in the presence of a normal kidney opposite the 
one in which renal artery stenosis was induced. In 1947 Braun- 
Menendez and Von Euler reported that hypertension could be induced 
2 
in rats from which the kidneys had been entirely removed. Two 
years later, using an electrolyte-free diet of casein, dextrose 
3 
and lard to prolong the lives of their animals, Grollman et al. 
were able to demonstrate a more prolonged elevation of blood pressure 
4 
in totally nephrectomized dogs. In 1951, Grollman et al. demon¬ 
strated that the hemodynamic state produced by renoprival hyper¬ 
tension in the rat was identical to that found in human malignant 
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hypertension. This state involved no change in blood volume, 
cardiac output or venous pressure from pre-hypertensive levels. 
Furthermore, they demonstrated identical tissue histopathology 
for the two hypertensive states, characterized by proliferative 
changes in the media of small and medium sized arterioles. Later 
5 
that year. Turner and Grollman were able to demonstrate the 
independence of renoprival hypertension from adrenal secretions, 
since bilateral adrenalectomy did not prevent elevation of arterial 
pressure. 
To better define the mechanism by which hypertension occurred, 
3 
Grollman et al. also performed dog experiments in which both 
kidneys were left in place with the ureters ligated, and others 
in which one ureter was implanted into either the small bowel or 
abdominal vena cava and the contralateral kidney was removed. 
Finding that only in cases of bilateral nephrectomy did a sus¬ 
tained elevation of blood pressure occur, they concluded that 
intact renal tissue was essential for the maintenance of the normo- 
tensive state and that this function was independent from the 
organ's excretory function. Furthermore, they were the first to 
postulate that "hypertension of renal origin" must not be due 
solely to liberation of a pressure agent but must stem in part 
from the kidney's failure to perform some antihypertensive activity. 
These observations were partially confirmed by the subsequent 
finding that renoprival hypertension could be dramatically reduced 
within hours by either isolated renal perfusion or renal trans- 
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plantation'7, even in the presence of continued high sodium and 
water intake. Again it was noted that the blood pressure lowering 
effects of the kidney were not due merely to loss of water and 
salt by diuresis since adequate salt and water replacement of 
urinary losses was provided, no sudden change in animal body weight 
occurred, and radioactive labelling techniques failed to reveal 
a change in either extracellular fluid or blood volume. 
O 
In another series of experiments, Muirhead and co-workers 
explanted whole kidney and medullary and cortical fragments to 
the peritoneum and lungs of dogs before and after renal ablation. 
In bilaterally nephrectomized control animals and those in which 
only renal cortex had been explanted, the expected rise in blood 
pressure was observed. In animals receiving explanted renal 
medulla, however, protection against renoprival hypertension 
was conferred. Subsequently, these same investigators demonstrated 
the ability of an intravenously administered saline extract of 
renal medulla to blunt the hypertensive effects of bilateral 
nephrectomy in dogs, as well as to lower blood pressure in dogs 
9 
in which renoprival hypertension had already been established. 
At the same time, extracts of spleen, lung, and erythrocytes 
failed to alter the course of renoprival hypertension. 
Once the renal anti hypertensive "factor" had been localized 
to the medulla, efforts were made to refine and characterize it. 
In 1964 Hickler and co-workers^ reported that the "depressor 
activity" of crude medullary homogenates was localized in the 
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lipid phase following extraction from acidified renal medullary 
tissue. Following this work, Lee and co-workers^ published a 
major paper reporting isolation and characterization of three 
acidic lipid vaso-depressor substances using column and thin- 
layer chromatographic techniques on a variety of solvent extrac¬ 
tions of renal medullary tissue. Production of a sustained 
blood pressure depression in the normotensive vagotomized pento- 
1inium-treated rat was the assay employed. While only two of 
the three acidic lipid substances were found to cause significant 
lowering of blood pressure, all three were found to stimulate 
non-vascular smooth muscle to varying degrees., Of a number of 
acidic lipid substances known to have such properties at the time, 
Lee's group selected prostaglandins as a broad series of compounds 
with similar characteristics with which to compare the newly iso¬ 
lated renomedul1 ary compounds. 
Chemically, Lee demonstrated strong similarities between the 
prostaglandins and his own renomedul 1 ary acidic lipids.^ These 
were listed as follows: 
1) Both were ethanol soluble and completely lipid extract- 
able from an acid aqueous phase but only incompletely 
extractable from an alkaline aqueous phase. 
2) Infrared spectroscopy revealed the presence of carbonyl 
and methylene groups "with evidence for the existence 
of hydroxyl groups and trans ethylene bonds" in both 
groups of compounds. 
3) Two of Lee's three compounds ("Medullin" and "Compound 1" 
as opposed to "Compound 2") shared similar UV spectra 
with prostaglandins of the E series. 
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Lee also noted some differences in chemical properties 
between medullin and the PGE series of compounds, however, de¬ 
spite their apparent structural similarities. Among these were 
the following: 
1) Medullin was found to be significantly more mobile 
than PGE compounds on thin layer chromatography. 
2) Medullin stained more intensely with iodine vapors 
than equal amounts of PGE-j. 
3) PGE-, in ethanol possessed no characteristic absorption 
at higher wavelengths, whereas a methanolic solution 
of medul1 in did. 
4) PGE-j was found to be 50 times more potent in stimu¬ 
lating non-vascular smooth muscle than medullin. 
In light of the above evidence, Lee concluded that medullin 
was a derivative of prostanoic acid with basic structural simi¬ 
larities to PGE-| but was more unsaturated and had fewer polar 
components (hydroxyl groups). This compound was later identified 
by Lee as a new prostaglandin, PGA^. At the same time, Lee 
identified his "Compound 2" as PGE^ on the basis of thin layer 
chromatographic mobility similar to PGE-| and the other properties 
listed above. Because Lee's "Compound 1" was less mobile than 
PGE and demonstrated strong non-vascular smooth muscle stimulating 
activity with absent or weak vaso-depressor properties--al1 charac¬ 
teristics common to PGF--Lee tentatively established the identity 
of "Compound 1" as PGF.^ 
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PROSTAGLANDINS AS VASO-ACTIVE SUBSTANCES 
Since the identification and characterization of the prosta¬ 
glandins, a great deal of work has been done to elucidate their 
effects and roles in cardiovascular and renal physiology. In 
virtually every laboratory animal studied, prostaglandins of the E 
series have caused a lowering of arterial blood pressure following 
parenteral administration. Among the animals studied have been 
.. . 12-15 . 16,17 . . 18 , . 18 .... 19,20 , . 16,21 
the dog, cat, rrlonkey, baboon, rabbit, and rat. 
In man, Bergstrom infused PGE intravenously at a rate of 
13 - 47 yg/min with the production of facial flushing, intense 
headache, cardiac palpitation, increase in heart rate varying from 
10-24 beats per minute, fall in systolic and diastolic blood 
pressure of from 15-27 and 15 - 31 mm Hg respectively, and the 
22 
development of severe chest and gastrointestinal discomfort. 
In addition, Bergstrom's group later demonstrated the ability of 
PGEi to blunt the pressor response to norepinephrine by as much 
23 24 
as 50%. More recently, Carlson and co-workers performed dose 
response studies on 8 human volunteers and found that at PGE-j 
infusion rates of 0.058 - 0.10 yg/kg/min cardiac output increased 
by a mean of 66%, heart rate by 27 beats per minute, and that mean 
arterial pressure fell by a mean of 8.0 mm Hg. At doses of 
0.18 - 0.32 yg/kg/min pulse rate increased another 7 per minute, 
cardiac output fell slightly due to smaller stroke volume, and 
mean arterial pressure decreased another 9 mm Hg, Peripheral 




In all the above studies, route and rate of administration 
of the E prostaglandins appeared to influence significantly the 
cardiovascular response to this group of compounds. In general, 
arterial, and particularly intrathoracic aortic injections of 
PGE produced more marked vaso-depression than intravenous admini¬ 
strations. Similarly, as the studies cited above indicate, a 
rapid intravenous injection of 50 yg of PGE^ produced a fall in 
blood pressure and a tachycardia whereas slow intravenous infusions 
of doses of this magnitude per minute were without effect in man. 
Furthermore, in order to reproduce the effects of a rapid 50 yg 
intravenous administration of PGE2, an intramuscular or subcu- 
25 
taneous dose 100 times as large was required. 
It was felt that the explanation for these differences might 
be related to rapid uptake, redistribution or metabolism of PGE 
26 
compounds. Using autoradiographic techniques, Samuelsson noted 
a high rate of uptake and concentration of labelled PGE-j in rat 
27 
lungs, a finding which prompted Anggard and Samuelsson to in¬ 
vestigate a possible role for the lung in prostaglandin metabolism. 
Using guinea pig preparations, they found that lung tissue contains 
a 15-hydroxy prostaglandin dehydrogenase which converts PGE and 
PGF compounds to two less polar inactive metabolites. Ferreira 
28 
and Vane later demonstrated the rapidity with which PGE can be 
removed from the circulation by perfusing intact liver and lungs 
with labelled PGE. They reported that in just one passage through 
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these tissues, 95% of an infused dose of PGE was removed and 
metabolized by the lungs, 70% by the liver. These findings 
were held to be consistent with evidence that PGE exerts greater 
effects when infused intra-arterially than intravenously. 
A number of mechanisms have been advanced to explain the 
blood pressure lowering effect of the E prostaglandins. In 
light of the ability of PGE to increase cardiac output while at 
11 1521 29 
the same time lowering arterial blood pressure, ’ ’ ’ and 
in light of a large volume of evidence developed from peripheral 
, . ... . .. , 15,30 .16 .11 , , 22-24,29,31 
perfusion studies in the dog, cat, rat, and human 
the most favored explanation centered on the ability of the E 
prostaglandins to decrease peripheral resistance. Of particular 
32 
note is the work done by Smith and co-workers using atropine, 
propranolol, and pyribenzamine in conjunction with PGE^ to demon¬ 
strate PGE-j's direct vasodilatory action independent of acetyl¬ 
choline, beta-adrenergic stimulation or histamine release. Simi¬ 
larly, it has been shown that neither pre-treatment with ganglionic 
14 30 33 14 . . 
blocking agents * ’ nor reserpine interferes with the ability 
of PGE-j to lower arterial pressure, suggesting further the direct 
action of PGE on peripheral vascular smooth muscle. 
In contrast to PGE compounds, PGF compounds show marked 
species related differences in cardiovascular effects. Anggard 
0/1 o r\ o r 
and Bergstrorri and Horton and Main, 5 for example, have demon¬ 
strated PGF compounds to be vaso-depressor in the cat and rabbit, 
36 37 15 38 
whereas DuCharme and Weeks ’ and Nakano and co-workers ’ 
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demonstrated them to be vasopressor in rats and dogs. In humans, 
intravenous infusion of 4.0 yg/kg/min of PGF^ for 60 minutes 
and intramuscular and subcutaneous doses of 20 mg were without 
25 39 
effect on blood pressure or heart rate. * Rapid single intra¬ 
venous injection of 500 mg of PGF0 , however, has been shown to 
ca 
Of 
elevate blood pressure. 
As shown by peripheral perfusion studies, the mechanism of 
PGF^'s vascular effect once again appeared to involve largely 
direct peripheral vasoconstriction or dilatation rather than 
centrally mediated phenomena. Perfusion of the hind limb of a 
dog with PGF^, for example, demonstrated that PGF^ has a veno- 
constrictor action versus an arteriolar smooth muscle stimulatory 
action, and it has been suggested that PGF9^ exerts its blood 
pressure elevating effect by increasing venous return and cardiac 
3 6 3 ~J 
output. ’ In these studies, pre-treatment with hexamethonium 
and reserpine also failed to block the PGF^ effect. Another 
38 
mechanism has been advanced by Nakano and Cole, who attribute 
at least part of PGF^'s blood pressure elevating effect to a 
direct increase in myocardial contractility. As for PGF^'s 
depressor qualities in some species, a number of investigators 
have shown PGF^ to directly dilate blood vessels in muscle but 
34 35 
not those of the kidney or skin in the cat. ’ 
Prostaglandins of the A series, while much less active than 
PGE in stimulating non-vascular smooth muscle, have substantial 




group. Weeks, and others. As is the case with PGE, PGA 
produces a decrease in blood pressure with a concomitant increase 
1 5 31 40-42 
in cardiac output in all laboratory animals studied. ’ ’ 
Once again decrease in peripheral resistance has been implicated 
as the mechanism involved. 
A AND E PROSTAGLANDINS AS ANTI-HYPERTENSIVE HORMONES 
Perhaps because PGA^ was isolated and characterized by Lee 
in the search for a renal anti-hypertensive "factor", much of the 
investigational interest in the PGA compounds has been directed 
toward determining a possible role for the renal prostaglandins 
in the physiology of hypertension. Lee found that a single intra¬ 
venous injection of 50 yg of PGA^ into a 25 year old hypertensive 
subject transiently lowered the blood pressure from 185/116 to 
160/95 mm Hg within 18 seconds.^ At the same time, heart rate 
reflexly increased from 102 to 114, cardiac output increased from 
8.4 to 9.5 liters/min and calculated peripheral resistance fell 
from 17.5 to 14.1 peripheral resistance units. With prolonged 
infusion of 382 yg/min in the same subject, blood pressure fell 
from 186/114 to 165/97 mm Hg and was maintained at this level for 
the duration of the infusion. A marked diuresis occurred during 
the infusion, but side effects such as headache, chest oppression 
and gastrointestinal cramping, which had occurred in experiments 
with PGE-j infusion, were absent. These findings have been corrob- 
39 43 
orated in other studies as well. ’ 
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More recently, evidence has been presented which indicates 
that E and A prostaglandins have actions which may influence 
blood pressure in ways other than by simple vaso-depression as 
well. In both dogs' and man PGE and PGA have been shown 
to increase renal blood flow, urine volume, free water clearance, 
and sodium and potassium excretion. Using graduated doses of PGA, 
49 50 
Westura and Carr both demonstrated that the earliest effect 
of PGA is a rise in sodium excretion and urinary flow, which is 
then followed by the expected blood pressure lowering response at 
51 
higher doses. Furthermore, Fichman and co-workers have presented 
data suggesting that PGA increases aldosterone secretion in man 
independent of changes in serum electrolytes, renin, or ACTH levels 
Thus mechanisms have been discovered by which PGE and PGA may in¬ 
fluence both immediate and longer term regulation of blood pressure 
With evidence revealing the anti-hypertensive properties of 
PGA and PGE continuing to grow, Lee in particular has been a pro¬ 
ponent of the theory that these prostaglandins, and PGA in parti¬ 
cular, may play active physiological roles in blood pressure and 
sodium homeostasis as circulating anti-hypertensive hormones. 
As Lee and others have pointed out, in contrast to many other anti¬ 
hypertensive agents, PGE and PGA not only spare renal function but 
increase renal blood flow, urine formation, and salt excretion. 
Thus a balance is established between the hormones' blood pressure 
lowering effect and renal perfusion. Secondly, evidence has been 
presented which indicates that PGE and PGA compounds cause a 
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redistribution of blood flow from renal medulla to cortex, an 
action which would tend to counter stimulation of renin release 
from cortically located juxtaglomerular apparatuses at times of 
52 53 
abnormal renal cortical ischemia. ’ Thirdly, of particular 
significance was the finding that PGA compounds, unlike PGE and 
PGF, are relatively unaffected by the 15-hydroxy prostaglandin 
dehydrogenase present in lung tissue and are more slowly metabo- 
42 54 
lized in the liver of most species. ’ As Lee points out, 
slower metabolism could also explain why PGA, despite its presence 
33 55 
in smaller amounts in renal medulla than PGE, ’ has greater 
cardiovascular effects than the E prostaglandins when administered 
42 49 
intravenously ’ and why it is therefore a more likely candidate 
as a possible circulatory anti-hypertensive hormone. Finally, 
Lee has proposed that in some forms of hypertension, if his theory 
is correct, a deficiency in the body's ability to synthesize, re¬ 
lease, and maintain adequate levels of circulating prostaglandins 
48 
might be expected. 
Factual support for Lee's concept of PGA as a circulating 
natriuretic anti-hypertensive hormone awaited the development of 
rapid sensitive assay techniques for the prostaglandins. Among 
the most successful of these have been the radioimmunoassay 
56 57 
techniques developed by Caldwell et al. ’ Armed with these 
techniques, Zusman demonstrated that in normal humans subjected 
to dietary salt restriction and loading, PGA levels respectively 
58 
rise and fall in parallel with plasma renin levels. In so doing. 
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he refuted Lee's concept of PGA as a circulating natriuretic 
hormone and Lee's prediction that a high sodium intake would 
be associated with an elevation of PGA to facilitate sodium 
48 
excretion. Rather, just the reverse relationship was found 
to hold true. To explain this finding, Zusman postulated that 
sodium restriction would lead to an elevation in renin levels 
58 
and angiotensin production as discussed by Mulrow and Goffinet. 
Angiotensin, which has been shown to stimulate release of prosta- 
59 
glandin-like material into renal venous effluent, would result 
in elevation of prostaglandin output, which would then tend to 
moderate the hypertensive effect of the elevated angiotensin 
fin 
levels, as demonstrated by Herbaczynska-Cedro and Vane. 
Furthermore, the elevated prostaglandin levels would tend to 
51 
stimulate secretion of aldosterone as demonstrated by Fichman, 
thus tending to stimulate sodium reabsorption and a return toward 
normal sodium levels. 
After establishing 1.60 ng/ml as the approximate level of 
circulating PGA in venous blood of normal humans, Zusman then 
found that in both patients with essential and renovascular hyper¬ 
tension, PGA levels were markedly lower than in normal humans, 
fi 1 
averaging in the range of 0.60 - 0.70 ng/ml. Furthermore, in 
these hypertensive patients no correlation could be made between 
PGA and plasma renin activity levels. This finding suggested to 
Zusman that perhaps "the normal interplay between these two vaso¬ 
tonic substances had been disturbed." In addition, in those 
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patients with renal artery stenosis, he was able to demonstrate 
significantly higher levels of PGA in renal venous blood than 
in peripheral venous blood, supporting the contention that the 
kidney is a major source of circulating prostaglandins. In his 
work Zusman was unable to demonstrate variations in the levels 
of circulating PGE or PGF, but as he rightfully points out, meta¬ 
bolism of these compounds by the lungs is in all likelihood so 
rapid as to preclude meaningful measurement of them in peripheral 
plasma. Furthermore, with the recent discovery of enzyme systems 
in human kidney and plasma with the capability of converting PGE 
to PGA, ’ J Zusman suggests that enzymatic conversion of PGE, 
which has been found to account for 60% of renal medullary prosta- 
64 
glandin content versus 15% for PGA, may contribute importantly 
to circulating PGA levels. 
Zusman's contribution to our understanding of prostaglandin 
physiology was his demonstration of the interdependence of sodium 
intake and PGA levels, presumably in the maintenance of sodium 
homeostasis, and his finding of abnormalities in PGA synthesis or 
release mechanisms in essential and renovascular hypertension. 
He has summarized his concept of a possible role for PGA in sodium 
and blood pressure homeostasis in Figure 1. If, as evidence 
suggests, this conception is an accurate one, investigational 
attention must be focused on those specific stimuli that may cause 
prostaglandin synthesis and release, for it is presumably some 
defect in these mechanisms that underlies the abnormalities Zusman 
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and others have found associated with essential and renovascular 
hypertension. 
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Figure 1. Zusman's conception of the role of PGA in sodium and 




PURPOSE OF THIS INVESTIGATION 
It is the purpose of this investigation to explore in greater 
depth some of the specific stimuli that have been implicated in 
causing elevation of circulating prostaglandin levels in blood 
pressure homeostasis. As noted previously, McGiff and co-workers 
have demontsrated that prostaglandin-like material appears in the 
venous effluent of the isolated perfused dog kidney in response 
59 
to renal artery infusion of angiotensin II. Such a stimulus- 
response relationship has never been demonstrated in the intact 
animal, however, particularly under conditions in which blood 
pressure is abnormally elevated. Furthermore, no effort has as 
yet been made to clearly differentiate whether this stimulus- 
response relationship is specific for the renin-angiotensin system 
or whether it obtains as well for other stimuli tending to elevate 
blood pressure--catecholamines, for example. 
To better define this relationship, experiments were designed 
in which angiotensin II and norepinephrine were infused into 
normal anesthetized animals to cause blood pressure elevation 
on an acute basis. Before, during, and after infusion, blood 
samples were drawn for the determination of renin activity and 
prostaglandin levels. 
In addition, similar procedures were carried out on monkeys 
in the third trimester of pregnancy to examine stimuli for the 
release of prostaglandins in the uteroplacental circulation, a 
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deficiency of which, Speroff has suggested, may be one of the 
mechanisms involved in toxemia, a hypertensive disease of preg- 
65 
nancy. Speroff bases his hypothesis on the following historical 
findings: 
66 67 
1) Young ’ first postulated uteroplacental ischemia 
as a cause of toxemia, a postulate consistent with 
the increased incidence of toxemia noted in women 
with vascular disease, fibroids, anemia, twin preg¬ 
nancy, or primigravid uterus. Beker (68) confirmed 
the larger caliber of multiparous uterine arteries 
by barium injection of bovine and human specimens. 
2) Experimental compromise of uterine circulation in a 
variety of animals by a variety of techniques produced 
blood pressure elevation in pregnant animals but did 
not do so in non-pregnant animals. (69-74) 
3) Pressor activity has been found in placental and 
uterine extracts by a number of investigators who 
have compared or identified the substance as renin. 
(75-78). 
4) Renin release by the uteroplacental unit has been found 
to behave independently from renal output of renin. 
(79,80). 
5) Toxemia has been found to be associated with a 40-60% 
reduction of blood flow through the uteroplacental 
unit (81,82), a reduction which has been found by 
dehydroepiandrosterone sulfate clearance studies to 
begin some time before the clinical appearance of 
hypertension (83,84). 
6) Ferris and co-workers (85) have demonstrated in the 
rabbit that a reduction in uterine blood flow causes 
an outpouring of renin in the uterine vein, whereas 
administration of angiotensin increases uterine blood 
flow. 
7) Ryan and co-workers (86) have found that acidic extrac¬ 
tion of placental tissue yields a substance with blood 
pressure lowering and smooth muscle stimulating effects 
similar to PGE. Furthermore, they found that toxemic 
placentas contained less of this substance than normal 
placentas. 
Putting this picture together, Speroff has suggested that 
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during pregnancy increased uterine pressure, twin pregnancy, the 
primiparous state, or a variety of other factors predisposing to 
uteroplacental vascular insufficiency may result in liberation 
of increased levels of renin. This renin would increase levels 
of circulating angiotensin which would result in increased blood 
flow through the uteroplacental bed and stimulate the output of 
prostaglandins by the placenta to help reduce resistance to blood 
flow through the placental bed. The hypertension of the toxemic 
state, Speroff suggests, may be characterized in part by defective 
prostaglandin production, loss of response to prostaglandin, or 
a combination of these. 
This investigation was conceived to study the interaction of 
certain blood pressure elevating stimuli and prostaglandin output 
responses in blood pressure homeostasis. Angiotensin and norepi¬ 
nephrine infusion were the stimuli employed in normal rhesus 
monkeys from which plasma samples were obtained at various times 
before, during, and after infusion for assay of the prostaglandins 
and renin activity. A more extensive investigation involving 
angiotensin infusion in rhesus monkeys in the third trimester of 
pregnancy was also carried out to determine whether elevated angio¬ 
tensin levels do in fact stimulate prostaglandin output in uterine 
venous blood, to determine the relationship between renin activity 
and prostaglandin levels in these samples, and to study the effect 




DEGENERATION OF 4——--UTERINE I Plocental 
TROPHCBLAST ISCHEMIA U Prostaglandins 
Figure 2. Speroff's Hypothesis for the Role of Prostaglandins 
in the Development of Toxemia of Pregnancy. 
(With permission of the author) 
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angiotensin analogue, on this system. It is hoped that by eluci¬ 
dating some of the mechanisms of blood pressure homeostasis in 
pregnant and non-pregnant states a broader understanding of the 
pathophysiology of hypertension in these states will be achieved. 
EXPERIMENTAL STUDIES 
RENIN ACTIVITY AND PROSTAGLANDIN A AND E LEVELS IN RESPONSE TO 
ACUTE BLOOD PRESSURE ELEVATION IN NON-PREGNANT MONKEYS 
Materials and Methods 
Experiments were carried out in normal non-pregnant female 
Rhesus Macaca mulatta monkeys ranging in weight from 5.0 to 6.5 kg. 
Only monkeys with a blood pressure no higher than 110/70 mm Hg at 
the start of the experiment were used. Monkeys inparticular were 
selected as experimental animals for the following reasons. First, 
being primates, they are as close to a human physiologic model as 
could reasonably be found. Secondly, the existence of a plasma 
isomerase spontaneously converting PGA to physiologically inactive 
87 
PGB has been demonstrated in the rabbit, cat, dog and rat. In 
humans, however, there is strong evidence that this isomerase does 
OO 
not exist. Because of the possibility of cross reactions between 
the PGA antiserum employed in our radioimmunoassay and PGB, we felt 
it might be difficult to derive statistically significant results 
from animals known to harbor the isomerase. No isomerase has as 
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yet been identified in the monkey. 
The monkeys were first tranquilized with 8.0 mg of Sernylan 
intramuscularly and then brought to the operating room where an 
intravenous infusion of 5% dextrose in water was begun in the left 
forearm at a rate just sufficient to keep the vein open. The 
monkeys were then either anesthetized with intravenous pentobarbital 
or intubated and anesthetized with halothane. Different methods 
of anesthesia were employed to insure that a given method of 
anesthesia did not introduce what would otherwise have been un¬ 
recognized effects upon the data. 
After the monkeys were adequately anesthetized, the right 
antecubital fossa was prepared and a cut-down was performed. The 
brachial artery was isolated and cannulated with a polyethylene 
cannula attached to a Corometrics pressure transducer to produce 
a continuous tracing of systolic and diastolic blood pressure. 
Either inguinal region was then prepared and a cut-down on the 
femoral vein performed. A polyethylene cannula was then inserted 
into the femoral vein and advanced far enough to insure that its 
tip was at or beyond the level of the entrance of the renal veins 
into the inferior vena cava. This cannula was used to obtain 
blood samples for the duration of the experiment. 
After the cannulas had been placed and the condition of the 
monkey had stabilized, two 10 ml blood samples were drawn at 
fifteen minute intervals for control purposes and to establish a 
baseline for renin activity and prostaglandin levels. A slow 
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infusion of either angiotensin II (Beckman) in four monkeys, or 
norepinephrine (Winthrop) in three monkeys, was administered by 
Harvard constant infusion pump into the peripheral intravenous 
line at starting doses of 0.06 yg/min and 1.6 yg/min respectively. 
In all cases blood pressure began to rise within five minutes of 
the start of infusion. Dosage of both drugs was titrated empiri¬ 
cally using as endpoints either an approximate 75% increase in 
systolic or diastolic pressure or the development of irregularities 
in the blood pressure tracing judged to be indicative of a cardiac 
arrhythmia. If a cardiac arrhythmia was judged to have developed, 
dosage was reduced just enough to cause its disappearance. In all 
cases at least a 30 mm Hg increase in systolic and diastolic 
pressure was achieved. Maximal doses averaged 0.24 yg/min of 
angiotensin and 6.4 yg/min of norepinephrine. 
When blood pressure had stabilized at a satisfactory level, 
usually within 10 - 15 minutes after starting infusion, three 10 ml 
blood samples were drawn from the femoral vein cannula at approxi¬ 
mately 10 minute intervals, after which the infusion of angiotensin 
or norepinephrine was discontinued. When blood pressure had dropped 
to and stabilized at pre-infusion levels (or below in some cases), 
usually within 10 minutes, two more 10 ml blood samples were 
obtained at 15 minute intervals to establish a post-infusion base¬ 
line. In addition, one or two simultaneous arterial blood samples 
were drawn from the brachial artery cannula during and after in¬ 
fusion for arterio-venous comparison of renin activity and prosta- 
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glandin levels. The cannulas were then removed, the wounds closed 
with subcuticular chromic sutures, and the animal returned to its 
cage after intramuscular injection of 1.0 cc of Combiotic, a 
veterinary preparation of of penicillin and streptomycin. 
Once obtained, each 10 ml blood sample was divided into a 
7.0 ml aliquot put into a heparinized conical centrifuge tube for 
prostaglandin assay and a 3.0 ml aliquot put into a tube containing 
EDTA for assay of renin activity. Both aliquots were immediately 
centrifuged and the plasma decanted and rapidly frozen in dry ice 
and methanol for storage until assay. The remaining red cells, 
approximately 5 cc for every 10 cc of blood drawn, were reinfused 
via the femoral vein cannula immediately after the following 10 cc 
blood sample had been collected to avoid the development of anemia. 
During the experiment each animal received approximately 50 cc of 
its own packed red cells and at least 50 cc of fluid in the form 
of D5W and heparinized 0.9% saline flushes to keep the cannulas 
open, thereby approximately replacing the 90 cc of blood drawn 
during the experiment. 
Prostaglandin Radioimmunoassay 
The methodology employed for the radioimmunoassay, which was 
carried out for PGA and PGE in this series of experiments, is 
56 57 
essentially as reported by Caldwell et al. and Zusman et al. 
EXTRACTION was carried out as follows: Tritium-labelled 
prostaglandin, approximately 1000 cpm, was added to 0.5 ml of 
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plasma to serve as a tracer for recovery. Recovery throughout 
the assay averaged 60% for PGA and 85% for PGE. The plasma was 
acidified to pH 3.5 - 4.0 with 0.1 ml of HC1. The samples were 
extracted with redistilled ethyl acetate, 7 ml for each 0.5 ml 
of plasma extracted, dried under air, and re-dissolved in a 
solvent system consisting of a 60/40/2 ratio of benzene/ethyl 
acetate/methanol in preparation for column chromatography. 
CHROMATOGRAPHY was performed using silicic acid minicolumns 
(0.5 gm silicic acid in a column 1.0 x 15 cm). The elution 
pattern obtained is diagrammed in Figure 3 along with the solvent 
systems employed. It should be noted that although the various 
classes of prostaglandins can be separated, the technique cannot 
distinguish between prostaglandins within a family, e.g. PGE-j and 
PGE^. Therefore results are reported as concentrations of PGA 
and PGE. 
RADIOIMMUNOASSAY followed the procedures described in the 
references cited above using PGA antiserum prepared by covalently 
linking PGE^ to bovine serum albumin by reaction with carbdiimide 
56 
reagent as described by Caldwell et al. for PGF^. The resulting 
compounds were then injected into rabbits from which the anti¬ 
bodies were later obtained. Cross reactions for our PGA anti¬ 
serum are illustrated in Figure 4. The antiserum used in measuring 
the E prostaglandins was obtained from Dr. Robert Skarnes of the 
Worcester Foundation. Full characterization has been published 
by Dr. Skarnes. Studies from our own laboratory reveal that 50% 
binding of the E antiserum occurs with 0.5 ng/ml of PGE-j , 80 ng/ml 
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°f PGF^, 93 ng/ml of PGA^, and 650 ng/ml of PGB^. Furthermore, 
all three of our antisera (PGA, PGE, and PGF) have been tested 
with the 15-keto and 13,14-dihydro,15-keto derivatives of the E, 
F, and A prostaglandins. The cross reaction with all derivatives 
and each antiserum is no greater than 0.1%. 
VALIDATION OF THE ASSAYS for precision has been carried out 
by measuring increasing amounts of prostaglandin added to a known 
low level plasma pool as illustrated in Figure 5. For assessment 
of reproducibility, plasma pools containing low and high prosta¬ 
glandin concentrations were run with each assay. The coefficient 
of variation for between (inter) and within (intra) assay repro¬ 
ducibility has been approximately 10% for each assay. 
Radioimmunoassay for Plasma Renin Activit.y 
Plasma renin activity was determined by measurement of the 
angiotensin I generated in vitro. The pH of 1.0 ml aliquots of 
each sample was adjusted to 6.0 with 0.2M maleate buffer, pH 6.0. 
Separate aliquots of the samples were then incubated in the pre¬ 
sence of inhibitors of the converting enzyme and angiotensinase 
for one hour at 37°C or 4°C. At the end of the incubation period, 
all samples incubated at 37°C were matched against their 4°C con¬ 
trol in an ice bath and the angiotensin I measured by radioimmuno¬ 
assay. The angiotensin I assay was carried out by a modification 
90 / 
of the Haber method using the radioimmunoassay materials (anti- 
125 




reagents and protocol supplied in the Angiotensin I ( I) Radio¬ 
immunoassay Kit distributed by the New England Nuclear Corpora¬ 
tion (Boston, Mass.)* Separation of antibody-bound and free angio- 
tensin I (I) was achieved by differential adsorption of the 
free antigen on activated charcoal followed by centrifugation. 
91 
The results were calculated using the logit transformation, 
and plasma renin activity was expressed as nanograms of angio¬ 
tensin I formed per ml per hour (ng/ml/hr). All values were cor¬ 
rected for the "angiotensin I" measured in the control samples 
incubated at 4°C. To eliminate the influence of assay to assay 
variability, all samples from a given experiment were measured 
in the same assay. 
Using this radioimmunoassay system, the lower limit of sensi¬ 
tivity for the assay was found to be 0.01 - 0.02 ng angiotensin I 
(unpublished results). The intra-assay coefficient of variation 
for 7 replicate samples from a plasma standard with a mean renin 
activity of 7.85 ng/ml/hr was 4.8%. The quantity of angiotensin I 
generated in vitro was found to be proportional to the time of 
incubation for at least 1.5 hr. After addition of charcoal there 
was no significant stripping of the antigen-antibody complex for 
a period of at least 20 minutes. 
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Figure 3. Elution Patterns of Prostaglandins A, B, 
via Silicic Acid Column Chromatography. 




x t5 keto PGEg 
O 13,14 dihydro 15 keto PGE2 
A 15 keto Fgc 
O 13,14 dihydro 15 keto F2a 
• PGA 
v PGB2 






Figure 5a. Addition of Known Amounts of PGA to a Low Level 
Plasma Pool. 




Results--Non-Pregnant Monkeys Receiving Angiotensin 
A summary of radioimmunoassay results for PGA, PGE, and 
plasma renin activity for this series of monkeys will be found 
in Tables 1 - 3. From this data an average pre-infusion level 
for each substance was determined from the mean of the two pre¬ 
infusion blood samples from each monkey. This level was considered 
as baseline for comparison with hormone levels obtained during 
the period of angiotensin infusion. The results were expressed 
as per cent change from baseline during infusion and were then 
pooled for purposes of statistical analysis. Mean per cent 
change for each substance from baseline and standard error of 
the mean were then calculated for all observed points during 
infusion with "P" values determined by T^ ^ test. 
Prostaglandin A 
In all four monkeys, regardless of anesthesia used, acute 
elevation of blood pressure with angiotensin II was associated 
with an average 26% decrease in inferior vena caval levels of 
PGA. This change was significant to P < .001. It was found in 
addition that baseline levels of PGA varied markedly from monkey 
to monkey, with two point pre-infusion averages for each monkey 
ranging from 0.17 to 1.03 ng/ml. When plotted against time, the 
PGA levels displayed peaks and depressions which fell at random 
and could not be correlated with concurrent renin or PGE data or 
with subtle changes in blood pressure recorded before, during, or 




A 29% decrease in inferior vena caval levels of PGE, signi¬ 
ficant at P < .001, was associated with blood pressure elevation 
with angiotensin II. In general, PGE levels were markedly higher 
than PGA levels in any given monkey, often by a factor of 5 or 
more. As with PGA, however, no correlation could be made between 
random peaks and depressions of PGE levels in individual monkeys 
and concurrent renin data or subtle changes in blood pressure 
recorded before, during, or after angiotensin infusion. 
Plasma Renin Activity 
Plasma renin activity consistently fell from baseline levels 
by approximately 45% in response to angiotensin infusion. This 
change was significant at P < .001. The decline was most marked 
during the first 10 minutes of angiotensin infusion, after which 
PRA levels either continued a slow decline or plateaued for the 
duration of the infusion. Following cessation of the infusion, a 
sharp rise in plasma renin activity back to pre-infusion levels 
was noted for all four monkeys. These patterns held true irrespec¬ 
tive of type of anesthesia used and appeared to reflect more the 
dose of angiotensin infused at a given time than the simultaneous 
blood pressure response. 
Results--Non-Pregnant Monkeys Receiving Norepinephrine 
A summary of radioimmunoassay results for PGA, PGE, and plasma 




In all three monkeys studied, no significant change in cir¬ 
culating venous PGA levels could be demonstrated in response to 
acute blood pressure elevation by norepinephrine infusion. Base¬ 
line levels of PGA ranged from 0.18 to 0.50 ng/ml with little 
variation during or after norepinephrine infusion. In general, 
blood pressure could not be elevated as high with norepinephrine 
as with angiotensin because of the increased incidence of cardiac 
arrhythmias produced by norepinephrine, but in all cases elevation 
of both systolic and diastolic blood pressure by approximately 
30% above baseline was achieved. 
Prostaglandin E 
As with PGA, no significant change in inferior vena caval 
levels of PGE could be demonstrated in response to norepinephrine 
infusion. In contrast to the PGA findings, however, baseline 
levels of PGE varied widely from monkey to monkey, ranging from 
0.36 to 3.33 ng/ml. In addition, although there was no statisti¬ 
cally significant change in PGE levels overall, the data indicate 
that PGE output from one blood drawing to the next was quite irreg¬ 
ular, with many random peaks and depressions that could not be 
correlated in time with specific simultaneous changes in PGA, 
plasma renin activity, or blood pressure. 
PIasma Renin Activity 
No significant change in plasma renin activity was associated 
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the three monkeys studied. Levels of renin activity at baseline 
were fairly consistent from monkey to monkey within a range of 
approximately 8 to 12 ng/ml/hr and remained within that range in 
almost all instances for the duration of the norepinephrine in¬ 
fusion. Following cessation of the infusion, levels of renin 
activity rose from 30 to 50% above baseline and either remained 
at this level or slowly declined for the duration of the experiment. 
Piscussion 
McGiff and co-workers have demonstrated that prostaglandin¬ 
like material is released into the renal venous effluent in response 
to arterial angiotensin infusion in the isolated perfused dog kidney 
The present series of studies, however, was unable to demonstrate 
such an output of either prostaglandin A or E in response to infu¬ 
sion of either angiotensin or norepinephrine in the intact anesthe¬ 
tized monkey; in fact, angiotensin infusion was associated with 
statistically significant decreases or approximately 25 and 30% 
for PGA and PGE respectively. These findings must be weighed in 
light of the following considerations. 
It is entirely likely that the kidney might behave differently 
in the isolated perfused state than in the living animal. It is 
almost certain that the intact animal would exert a variety of 
compensatory influences tending to moderate not only an initial 
stimulus, but perhaps even some of the physiological responses to 




of importance to the role of compensatory influences in the intact 
animal, the current study suggests that the role of prostaglandin 
output as an anti hypertensive mediator in response either to angio¬ 
tensin specifically or to acutely elevated blood pressure in a more 
general sense may be less obvious than originally inferred from 
McGiff's work with isolated perfused dog kidneys. 
On the other hand, the current study involved infusion of 
quantities of angiotensin and norepinephrine producing acute changes 
in blood pressure and vascular tone vastly greater than seen in any 
physiological or pathological condition with the possible exception 
of the hypertensive crisis of pheochromocytoma. It is possible 
that such intense degrees of renovascular vasoconstriction were 
achieved that the kidneys were unable to effect or maintain adequate 
prostaglandin output secondary to inadequate perfusion. In this 
case, one might have expected to see an initial burst of prosta¬ 
glandin output followed by a decline and plateau of output at rela¬ 
tively low levels. Since the first blood sample obtained following 
the start of infusion was taken only after blood pressure had stabi¬ 
lized at the desired hypertensive level, it is conceivable that 
an initial burst of prostaglandin output might have been missed. 
Future experiments will have to be arranged so that blood samples 
can be obtained continuously from the start of infusion. At present, 
work is also being done in pregnant monkeys to establish dose- 
response data to determine at what dose of angiotensin prostaglandin 
output, if any, will be at a maximum. 
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Unfortunately the current study can give no precise infor¬ 
mation as to the source of the prostaglandins being measured. 
Although the likelihood is great that this source is the kidney, 
this expectation can only be confirmed by direct sampling of renal 
venous blood, as was done by Zusman in his study of prostaglandin 
61 
levels in hypertensive humans. Early in the course of the current 
series of experiments, renal vein cannulation was attempted using 
Hypaque and fluoroscopy, but this technique was soon abandoned 
because of the poor tolerance of the monkeys to this procedure in 
our hands. The remaining experiments of this series were therefore 
carried out with the blood sampling cannula placed in the inferior 
vena cava at or above the entrance of the renal veins, and the 
blood sampled was thus an admixture of renal and vena caval blood. 
As such, it is possible that lower levels of the prostaglandins 
than expected were observed secondary to a decrease in the proportion 
of renal venous to vena caval blood in the samples obtained during 
the periods of renal vasoconstriction, which would tend to decrease 
the flow of renal venous effluent and even mask elevations in the 
concentration of prostaglandins being released by the kidney. Future 




UTERINE VENOUS RENIN ACTIVITY AND PROSTAGLANDIN LEVELS IN RESPONSE 
TO ACUTE BLOOD PRESSURE ELEVATION IN PREGNANT MONKEYS 
Materials and Methods 
These experiments were carried out in normal female Rhesus 
Macaca mulatta monkeys in the third trimester of pregnancy with 
weight ranging from 5.55 to 9.0 kg and day of gestation from 117 
to 140. 
In three monkeys, the procedure was as follows: Ketamine, 
2 mg/kg, was administered intramuscularly, and the monkeys were 
intubated and brought to the operating room. Under general anes¬ 
thesia achieved with halothane (50 ml/min) and oxygen (3 liters/min), 
an intravenous infusion of D5W was begun in the right forearm and 
the left brachial artery was cannulated with a polyethylene cannula 
attached to a Corometrics pressure transducer to produce a continuous 
tracing of systolic and diastolic blood pressure. The abdomen was 
then prepared and laparotomy performed to isolate either major 
uterine vein. The uterine vein was then cannulated and blood drawn 
and angiotensin infused as described in the previous experiments. 
Renin activity and prostaglandin radioimmunoassay were carried out 
as described above. At two times during each run, simultaneous 
arterial samples were drawn as well. 
In one monkey the same procedure was carried out except that 
following procurement of baseline bloods, angiotensin was infused 
for 20 minutes followed by a 20 minute return to baseline blood 
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pressure. Angiotensin infusion was then started again for a 30 
minute period, after 15 minutes of which a solution of 80 mg of 
indomethacin, a potent inhibitor of prostaglandin synthesis, was 
administered intravenously to determine its effect on blood pressure 
and plasma renin activity. The indomethacin solution was prepared 
92 
by the method of Preston as follows: The required amount of 
indomethacin was suspended in 3.0 cc of 0.9% saline and pH adjusted 
to 11 to produce a clear yellow solution using 1 normal NaOH. The 
pH was then titrated back to pH 7.4 - 8.0 using 1 normal HC1. The 
final amount of solution amounted to approximately 5 cc. During 
the course of the experiment, blood samples of 10 ml each were 
drawn at 15 - 20 minute intervals as previously described. 
In two monkeys exactly the same procedures were carried out 
as for the first three pregnant monkeys except that D5W was infused 
instead of angiotensin for control purposes. Near the end of these 
two experiments, a bolus of indomethacin solution was administered 
intravenously to each monkey, 20 mg to one and 40 mg to the other, 
in order to observe the effect of this drug on blood pressure and 
plasma renin activity. In addition, in the second control monkey, 
all blood samples were drawn slowly over a ten minute period, 
approximately 1.0 ml/min, rather than all 10 ml at once to make 
certain that no abnormal deviation in renin activity or prosta¬ 
glandin levels occurred as a result of rapid withdrawal of a large 
amount of blood from the monkey within a short period of time. 
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Results--Pregnant Monkeys Receiving Angiotensin 
A summary of radioimmunoassay results for PGA, PGE, PGF, and 
plasma renin activity for this series of monkeys will be found in 
Tables 7 - 12. 
Prostaglandin A 
In the first three monkeys receiving angiotensin as described 
in "Materials and Methods" above, no statistically significant 
effect of angiotensin-induced systemic hypertension on PGA levels 
in uterine venous blood could be demonstrated. In contrast to the 
inferior vena caval blood samples of the non-pregnant monkeys, 
uterine venous PGA levels in pregnant monkeys were fairly consis¬ 
tent from monkey to monkey at a baseline of approximately 0.50 ng/ml. 
Throughout the experiments, PGA levels fluctuated between levels 
of approximately 0.35 and 0.60 ng/ml in such a fashion that no 
correlation could be made between PGA levels and levels of the 
other prostaglandins, plasma renin activity, or subtle fluctuations 
in systemic blood pressure recorded before, during, or after angio¬ 
tensin infusion. Because no statistically significant correlation 
could be made between angiotensin infusion and changes in PGA levels, 
PGA was not assayed in the control monkeys. 
Prostaglandin E 
In the same three pregnant monkeys reported above, a mean 
increase of nearly 50% above pre-infusion baseline levels was 
demonstrated for uterine venous PGE levels in association with 
angiotensin-induced systemic hypertension. This change was signifi- 
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cant at P < .05. Uterine venous baseline PGE levels averaged 
approximately 1.0 ng/ml within a range of 0.67 to 1.64 ng/ml. 
In one instance the increase in PGE was gradual during the course 
of the infusion, but in the other two the increases were charac¬ 
terized by rather sharp spikes followed by declines to near base¬ 
line levels. The timing of the spikes during the course of the 
angiotensin infusion was variable, however, and seemed to bear no 
consistent relationship to changes of blood pressure, renin, or 
the other prostaglandins during the course of the experiment. 
In one pregnant monkey submitted to a 20 minute angiotensin 
infusion, then allowed to restabilize, and then submitted to another 
angiotensin infusion at the end of which 80 mg of indomethacin was 
administered intravenously, no significant elevation of uterine 
venous PGE levels occurred during the first period of infusion 
(Table 11). During the second infusion period there was again no 
elevation in PGE levels, which fell promptly to almost unmeasurable 
levels following indomethacin administration. Concurrent with 
indomethacin administration, a further elevation of systolic and 
diastolic blood pressure of approximately 15 mm Hg was observed. 
Of particular interest, however, was the fact that following the 
final angiotensin infusion, Caesarian section was performed on this 
monkey revealing a twin pregnancy. Both infant monkeys were alive 
at birth but were of low apgar, most likely secondary to maternal 
fell 
anesthesia. Unfortunately it was impossible to whether they shared 
a common placenta. 
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Two other pregnant monkeys were also infused with D5W followed 
by intravenous administration of 20 and 40 mg of indomethacin for 
control purposes. This data is presented in Table 12. In one 
monkey a rise in uterine venous PGE levels comparable to that ob¬ 
served in the three experimental animals was noted during D5W in¬ 
fusion. Near the end of D5W infusion the PGE level began to fall 
and continued to do so for approximately 15 minutes, after which 
it again rose without immediately apparent cause to 1.35 ng/ml 
from a baseline of 0.40 ng/ml. Following administration of 20 mg 
of indomethacin the PGE level fell to 0.15 ng/ml in association 
with a 15/15 mm Hg elevation of blood pressure. In the second 
control monkey, baseline uterine venous PGE levels averaged 1.0 ng/ml 
and rose during the course of D5W infusion to 3.30 ng/ml and to 
5.60 ng/ml immediately following cessation of the infusion. Imme¬ 
diately prior to administration of 40 mg of indomethacin, PGE 
levels dropped again to 1.83 ng/ml, and following indomethacin 
administration a further drop to 0.15 ng/ml was noted. Drawing 
of blood samples slowly over a 10 minute period versus all at once 
did seem to provide a smoother curve with fewer random peaks and 
depressions of prostaglandin levels observed. 
Prostaglandin F 
In the original three pregnant monkeys submitted to angiotensin 
infusion, a slight but statistically insignificant elevation of 
PGF levels was noted in association with angiotensin-induced sys¬ 
temic hypertension. Pre-infusion baseline levels of PGF averaged 
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0.63 ng/ml, and the pattern of PGF output was once again noted 
to be one of random peaks and depressions. Because no significant 
correlation could be made between angiotensin infusion and changes 
in PGF levels, PGF levels were not assayed in the control monkeys. 
Plasma Renin Activit.y 
In all four pregnant monkeys receiving angiotensin infusion, 
an average decrease in uterine venous plasma renin activity of 24% 
was noted in association with angiotensin-induced systemic hyper¬ 
tension. This change was significant at P < .05 and was similar 
to the pattern of change observed in the non-pregnant monkeys, 
although not as dramatic. In the two pregnant control monkeys, 
uterine venous plasma renin activity was observed to increase 
moderately during D5W infusion. The effect of indomethacin on 
plasma renin activity was variable. In one monkey during angio¬ 
tensin infusion, plasma renin activity rose from 3.32 to 25.67 
ng/ml/hr in response to 80 mg of indomethacin. In the two control 
monkeys, 20 and 40 mg of indomethacin produced no significant 
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D5W CONTROL INFUSION 
ON UTERINE VENOUS PGE AND RENIN--PREGNANT MONKEYS 
PGE Plasma Renin Acti 
ng/ml ng/ml/hr 
0.39 Pre-infusion— 12.91 
0.42 21.49 




0.47 Infusion Off— 37.06 
(1.34 (18.59 
(0.54 Art.(16.79 
(0.15 Indomethacin— (19.37 
(0.11 (20mg) Art.(14.36 
-(Bloods drawn slowly over 10 min) 
PGE Plasma Renin Acti 
ng/ml ng/ml/hr 




2.90 D5W infusion— 16.76 
(3.34 (14.64 
(1.81 Art.(13.14 
5.63 Infusion Off— 14.64 
1.85 18.51 
0.19 Indomethacin— 16.08 





This study demonstrates that acute elevation of systemic 
blood pressure by angiotensin infusion is associated with a signi¬ 
ficant increase in the release of prostaglandin E in the uterine 
venous blood of rhesus monkeys in the third trimester of pregnancy. 
Levels of prostaglandins A and F, however, remain unchanged. These 
findings suggest that prostaglandin E may play an important role 
in the regulation of vascular resistance in the utero-placental 
bed. The responsiveness of PGE rather than PGA also serves to 
underline the likelihood that the major effect of the response is 
directed locally rather than systemically. 
85 
As previously noted, Ferris and co-workers have demonstrated 
in the rabbit that a reduction in uterine blood flow causes an out¬ 
pouring of renin in the uterine vein and that administration of 
angiotensin increases uterine blood flow. In addition, Ryan and 
86 
co-workers have found that acidic extraction of placental tissue 
yields a substance with blood pressure lowering and smooth muscle 
effects similar to PGE. Results from the present investigation 
would seem to support the possibility that the mechanism by which 
angiotensin increases uterine blood flow is through release of 
prostaglandin E, although proof of this hypothesis awaits further 
investigation employing direct flow measurements across the utero¬ 
placental bed. The observation of a consistent arterio-venous 
difference in levels of prostaglandin E, with greater levels 
observed in uterine venous versus brachial arterial blood, points 
strongly to the utero-placental unit as the source of the PGE elevation. 
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Two pregnant monkeys in this study were treated as controls 
and received an infusion of 5% dextrose in water instead of angio¬ 
tensin II. In these monkeys sugnificant elevations of PGE were 
also noted to occur, but in contrast to the experimental animals, 
these elevations were associated with simultaneously rising levels 
of plasma renin activity. Because of this it is suspected that 
endogenously produced angiotensin may have been responsible in part 
for the rise in PGE levels that was observed, although the role of 
anesthesia and surgical stress cannot be overlooked. Experiments 
are currently underway using the angiotensin II analogue P-j^, 
which competes with angiotensin at its binding sites but exerts 
only slight hypertensive effects of its own, to elucidate further 
the role of exogenous and endogenous angiotensin II stimulation of 
prostaglandin production by the utero-placental unit. 
During three pregnant monkey experiments inhibition of prosta¬ 
glandin synthesis was achieved with varying doses of imdomethacin. 
In all cases, a rise in systolic and diastolic blood pressure of 
approximately 15 mm Hg was observed within five minutes of indo- 
methacin administration. This blood pressure increase was most 
marked in an animal receiving simultaneous angiotensin infusion 
but was also observed in the D5W control monkeys, suggestion again 
that suppression of prostaglandin synthesis and release mechanisms 
may be an important factor in this and other hypertensive states. 
Since the data for this thesis was tabulated, preliminary evidence 
has been produced by the use of Statham flow-measuring instruments 
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which does in fact demonstrate a decrease in uterine artery blood 
flow associated with the observed increase in blood pressure in 
response to indomethacin administration. This evidence tends to 
support the suggestion that prostaglandins may play an important 
role in maintaining decreased vascular resistance in the utero¬ 
placental bed. 
CONCLUSION 
The results of this study of non-pregnant monkeys do not tend 
to support the conception that prostaglandins, and particularly 
PGA, are secreted by the kidney in response to the pressor effect 
of elevated levels of either circulating angiotensin or norepi¬ 
nephrine. Despite this fact, however, and in light of the over¬ 
whelming evidence in support of an anti hypertensive role for the 
renal prostaglandins, the hypothesis that a defect in prostaglandin 
synthesis and release mechanisms is associated with many forms of 
spontaneously occurring hypertension remains an attractive one. 
This is particularly true in light of Zusman's finding of decreased 
levels of circulating PGA in humans with essential and renovascular 
6"i 
hypertension. The key questions in need of further clarification 
are what blood pressure related stimuli are directly responsible 
for influencing prostaglandin output and what defects in the 
stimulus-response pattern arise that may result in or stem from 
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the development of hypertension. 
One possibility that must be considered is that the renal 
prostaglandins, rather than responding to elevated angiotensin 
levels, increase in direct response to elevated renin levels. 
Although renin infusion, as such, has never been attampted, such 
information can be derived from studies using the angiotensin 
analogue P-| -j^ t° determine whether salt loading and depletion 
58 
studies such as that undertaken by Zusman will yield similar 
results in the absence of angiotensin II binding sites. 
The response of PGE in some but absence of PGA response in 
all of our studies suggests the possibility that PGA may not play 
an important role in modulating acute hypertensive stimuli. In 
view of the observation that 60% of the renomedullary prostaglandin 
content is in the form of PGE versus only 15% for PGA, there is 
a definite possibility that the first response to an acute hyper¬ 
tensive stimulus may be the output of PGE into local tissues to 
dt. 
exert local versus systemic vasopressor and natriuretic effects. 
It is also likely that for the maintenance of a refined day to day 
balance between hypertensive and antihypertensive influences in 
the normal animal, local renal adjustments in vaso-motor tone and 
sodium excretion might play a more important role than systemic 
vasodepression. In the face of chronic hypertensive stimuli, how¬ 
ever, PGA may be called upon to play a longer term systemic role 
in maintaining normotension. Such a hypothesis is consistent with 
the unresponsiveness of PGA observed in our acute experiments, 
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and it may be that a longer term hypertensive model will be re¬ 
quired if elevations in PGA are to be observed. In addition, this 
hypothesis is consistent with the depressed levels of PGA observed 
by Zusman in humans with spontaneous endogenous hypertension, in 
whom chronic stimulation of PGA output may have led to a "burning 
out" of renal medullary interstitial cell ability to produce the 
substance. 
Of interest throughout the entire series of infusions in both 
non-pregnant and pregnant monkeys was the pattern of prostaglandin 
output observed. Rather than remaining constant or smoothly rising 
or falling in response to the hypertension-producing infusions, PGA 
and PGE output tended to occur in a pattern of pulses followed by 
lulls or depressions in output until the next pulse. A similar 
59 
pattern of output has also been observed by McGiff and co-workers. 
93 
Palsrud has suggested an interesting scheme of enzyme kinetics 
for the prostaglandin synthetase enzyme to explain this phenomenon. 
According to this scheme, prostaglandin synthetase may only be able 
to undergo a limited number of active enzyme-substrate turnovers 
before becoming permanently inactive and requiring resynthesis. 
Although there is no factual support for this concept as yet, it 
would explain the lull following pulses of prostaglandin output, 
during which resynthesis of prostaglandin synthetase itself would 
be required. 
In the experiments on pregnant monkeys, it was especially 
exciting to find that the one pregnant monkey whose uterine venous 
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PGE levels did not respond to angiotensin infusion was carrying 
a twin pregnancy. The finding of an unresponsive pattern of utero¬ 
placental PGE output in a monkey with a type of pregnancy suspected 
of being associated with utero-placental vascular insufficiency 
strengthens the possibility that chronic uterine ischemia may ulti¬ 
mately be associated with decreased prostaglandin output by the 
86 
utero-pl acental unit. As previously mentioned, Ryan et al. ' have 
found that human toxemia placentas contain less of of a PGE-like 
substance than normal placentas. Although spontaneous development 
of the true toxemia state has never been reported in laboratory 
animals and has been produced only with considerable difficulty in 
94 95 
pregnant dogs and baboons by compromising uterine blood flow, 
the results of the present study are consistent with the contention 
that the hypertension of the toxemic state may be characterized in 
part by defective prostaglandin production. 
The pathophysiology underlying such a defect in prostaglandin 
production is as yet unknown, however data concerning the behavior 
of renin and angiotensin during normal and toxemic pregnancies 
permit the following speculation. In normal human pregnancy, it 
is nowgenerally recognized that circulating levels of renin and 
angiotensinogen, the plasma precursor of angiotensin, are frequently 
elevated above levels found in non-pregnant normotensive women. 
In a recent prospective study, pregnant women who subsequently 
developed toxemia had significantly higher plasma renin levels 
96 
than normal pregnant women in mid-trimester whereas another study 
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has demonstrated that by the third trimester, women with frank 
toxemia have markedly decreased levels of circulating renin, angio- 
97 
tensinogen, angiotensin II, and aldosterone. This pattern 
suggests that an underlying lesion of some sort, probably utero¬ 
placental vascular insufficiency, provides a stimulus for increased 
renin output, angiotensin production, and, according to the current 
study, increased output of prostaglandin E. Over a period of time 
the chronicity of the underlying vascular insufficiency and perhaps 
its increasing severity during the course of pregnancy might tax 
these homeostatic mechanisms to the point of exhaustion. Apparent 
exhaustion of renin output by the juxtaglomerular apparatuses of 
the kidneys in pregnant rats has already been induced by restriction 
98 
of sodium intake. A similar line of reasoning has also been used 
to explain the diabetogenic effects of growth hormone-secreting 
pituitary adenomas, in which increased levels of blood sugar secon¬ 
dary to the effects of the hormone are felt to cause overstimulation 
and subsequent "burn out" of the pancreatic islet cells. Factual 
support for such a model of toxemia awaits investigation of PGE 
levels in the second and third trimesters of human pregnancies at 
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